Published in Biotech Law Weekly, July 21st, 2006
ADCs utilize the targeting ability of monoclonal antibodies to deliver cell-killing payloads to tumor cells. Seattle Genetics' ADC technology employs synthetic, highly potent drugs, such as monomethyl auristatin E (MMAE), which are attached to antibodies through proprietary...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.